← Eichor
Condition: Anti Angiogenic Therapy Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Anti Angiogenic Therapy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06446154Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
Phase 1 · 2 location(s) · Lebanese University · NCT06307249Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT07025174Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
Phase 2 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT06360042Human Amniotic Membrane (hAM) for Stage II Maxillomandibular Osteonecrosis Management
Phase 2 · 5 location(s) · Centre Hospitalier Universitaire de Besancon · NCT05664815Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06371586TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension
Phase 2 · 1 location(s) · Fei Gao · NCT06646198Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial
Phase 2 · 4 location(s) · Fudan University · NCT06965231Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous M
Phase 2/Phase 3 · 1 location(s) · Fondation Ophtalmologique Adolphe de Rothschild · NCT06264531Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Phase 3 · 181 location(s) · AbbVie · NCT05407636CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 25 location(s) · Crescent Biopharma, Inc. · NCT07335497Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06482801ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06543836Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Secon
Phase 2 · 1 location(s) · The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer · NCT06662006A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06878625A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy
Phase N/A · 1 location(s) · Peking University Cancer Hospital & Institute · NCT06549907Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Phase 2 · 22 location(s) · Medical University of Vienna · NCT01356290
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.